Investing $1,000 in Zoetis (ZTS) shares a decade ago would have yielded you this much today.

Investing $1,000 in Zoetis (ZTS) shares a decade ago would have yielded you this much today.

Zoetis, a leading player in the animal health sector, has shown steady growth over the past decade. This growth trajectory continues to be a key focus for investors looking ahead to 2023 and beyond.

The company made its debut in 2013, spun off from Pfizer, and has since established a commanding market position across multiple animal health segments. In 2015, Apple introduced the Apple Watch, but it's Zoetis' growth story that has captivated the investment world.

Over the past decade, an investment in Zoetis (ZTS) stock would have grown by a total of 227%. Despite a few hiccups in the past one, three, or five years, which resulted in a loss of money, a $1,000 investment made 10 years ago would be worth approximately $3,270 now.

Zoetis' recent dividend yield of 1.3% underscores its status as a dividend-paying stock. The total annual dividend payout for Zoetis, recently $1.93 per share, is an increase from $1.30 in 2022 and $0.50 in 2018.

The company's financial performance is a testament to its strength and market demand. In 2024, Zoetis reported revenue of $9.26 billion, up 8.33% year-over-year, and earnings of $2.49 billion, up 6.06%. Q2 2025 showed 8% organic operational revenue growth.

Zoetis' growth rates are forecasted to be around 7.2% for earnings and 5.2% for revenue annually, with EPS expected to grow around 8.2% each year. Return on equity is high at 49%, showcasing efficient capital use and profitability.

Zoetis' strategic acquisitions have expanded its product lines and geographic reach, boosting high-margin segments. This diversification of revenue streams fuels long-term growth opportunities.

The animal healthcare sector is generally considered recession-resistant due to the necessity of animal healthcare for both business and personal reasons. Zoetis' business model benefits from this structural resilience.

Analysts have an overall "Buy" rating with a 12-month price target around $205, implying upside of roughly 33-34% from current levels. Shares experienced some underperformance, losing around 8% over the prior year, but analysts now see current prices as close to fair value and a good buying opportunity given solid fundamentals.

In summary, Zoetis is positioned for steady mid-to-high single-digit growth in revenue and earnings, underpinned by strong market share, ongoing acquisitions, and structural sector advantages. Its recession-resistant characteristics further enhance its appeal as a durable growth stock in the animal health space.

[1] Yahoo Finance: Zoetis (ZTS) [2] Seeking Alpha: Zoetis (ZTS) Q2 2025 Earnings Call Transcript [3] Zoetis Investor Relations: Q2 2025 Earnings Release [4] MarketWatch: Zoetis raises 2025 earnings outlook after $1.85 billion debt offering

1. Investors interested in Zoetis' growth, and personal-finance management, might consider that a $1,000 investment in Zoetis stock 10 years ago would be worth approximately $3,270 now, showing a significant 227% growth over the past decade.
2. In the realm of finance and investing, Zoetis' strategy of acquiring companies to expand product lines and geographic reach has contributed to its high-margin segments and diversification of revenue streams, opening up long-term growth opportunities.
3. For those focused on personal-finance and investing, Zoetis' stock is attractive not only due to its mid-to-high single-digit growth rates in revenue and earnings, but also because its business model benefits from the animal healthcare sector's recession-resistant nature, making it a durable growth stock in the animal health space.

Read also: